PARIS & HANNOVER, Germany--(BUSINESS WIRE)--Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical company, and Hannover Medical School, one of the world’s leading university medical centres, today announced that they have entered into a joint research collaboration agreement (signed last September). The objective is to develop new therapeutics for patients with serious neurological, endocrinological or oncological disease.
The research program aims at testing recombinant botulinum neurotoxin proteins to affect intracellular molecular pathways with targeted secretion inhibitors (TSIs). Ipsen’s proprietary platform of TSI proteins is selectively able to deliver neurotoxin endopeptidase into defined target cells and inhibit pathological secretion from that cell. This technology is based upon the endopeptidase activity found within clostridial (botulinum) neurotoxins, which cleaves SNARE proteins that have a fundamental role in vesicular cell secretion.
Help employers find you! Check out all the jobs and post your resume.
